News
All the latest news from Quadratech Diagnostics. If you would like to receive updates via our newsletter then please sign up here.
Quadratech 2012 Newsletter Back Issues
Back issues of Quadratech 2012 newsletters are available for viewing and downloading.
Intergrated Solutions: Cell Penetrating Peptides
Bio-Synthesis is a leading global manufacturer of high quality custom peptides and oligonucleotides. Their expertise includes the ability to design and manufacture advanced peptide-bioplymer bioconjugation for biopharmaceutical, diagnostic, and research applications.
Bio-Synthesis Inc. Introduces “BNA-NC”
Bio-Synthesis Inc. Introduces "BNA-NC" - A Third Generation Multi Functional Bridged Nucleic Acid Bio-Synthesis is proud to announce that it has acquired a license from BNA Inc. of Osaka, Japan for the manufacturing and distribution of BNA-NC, a third generation of BNA oligonucleotides. This agreement is valid worldwide and is meant for research use only at this time (Patents JP: 4731324(2011.4.28), USP: 7427672(2008.9.23), EP: 1551905(2012.4.25)).
New Products from Bio-Synthesis: GLYCOPEPTIDES
Biomedical Applications of Glycopeptides Diagnostics–Glycated peptides can serve as biomarkers to monitor the onset of diseases such as hyperglycemia, diabetes and its complications. Studies have shown that in diabetic patients,proteins including Hemoglobin A, Human Serum Albumin(HSA),Fibrinogen are extensively glycated. Diseases Therapy–age–related neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral sclerosis have been associated with increased AGE’s formation.Glycopeptides can therefore serve as biological markers to evaluate the efficacy of disease therapy.
New Assays For Measuring Direct Thrombin Inhibitors in Plasma
Direct Thrombin Inhibitors (DTIs) have increasing and promising curative, preventive or prophylactic applications in severe clinical situations. Laboratory methods are required for adjustment of drug efficacy and for avoiding overdosage. Specialized calibrated clotting and chromogenic assays for quantitating various DTIs have been developed and compared for their efficacy. Results show excellent performance with Hirudin and analogues, but were not found to be suitable for the Argatroban® usual therapeutic range.
55th Annual Meeting Society of Thrombosis and Haemostasis Research – [Dabigatran]
Dabigatran calibrator and control plasmas for drug measurement in plasma, when required Amiral J.1, Stangier J.2, Peyrafitte M.1 1HYPHEN BioMed, research, Neuville sur Oise, France. 2Boehringer Ingelheim Pharma Gmbh & Co KG, Biberach an der Riss, Germany
55th Annual Meeting Society of Thrombosis and Haemostasis Research – [PS]
Highly stable and robust protein S clotting assay validated for easier laboratory practice Amiral J.1, Peyrafitte M.2, Vissac A.M.2 1HYPHEN BioMed, Neuville sur Oise, France. 2HYPHEN BioMed, Research, Neuville sur Oise, France
55th Annual Meeting Society of Thrombosis and Haemostasis Research – [Anti-FVIII]
Development of an individual Anti-FVIII Inhibitors ELISA to improve Haemophiliacs therapeutic follow up Peyrafitte M.1, Vissac A.M.1, Amiral J.2 1HYPHEN BioMed, Research, Neuville sur Oise, France. 2HYPHEN BioMed, Neuville sur Oise, France
55th Annual Meeting Society of Thrombosis and Haemostasis Research – [MP-TF]
The multiple faces of tissue factor measured with laboratory assays Laroche M.1, Peyrafitte M.1, Vissac A.M.1, Amiral J.2 1HYPHEN BioMed, Research, Neuville sur Oise, 2HYPHEN BioMed, Neuville sur Oise, France
55th Annual Meeting Society of Thrombosis and Haemostasis Research – [TF]
Microparticles exposing Tissue Factor in human plasma Laroche M.1, Vissac A.M.1, Peyrafitte M.1, Amiral J.2 1HYPHEN BioMed, Research, Neuville sur Oise, France 2HYPHEN BioMed, Neuville sur Oise, France
NEQAS Blood Coagulation Annual Scientific Meeting September 2012
We had our usual space at this annual meeting and managed to sit in on some excellent presentations.
Update on Potential New Anticoagulants – www.pmlive.com
Modern anticoagulants threaten status quo. Could the shift towards first-in-class novel oral treatments, which are expected to prove beneficial for prevention of stroke caused by AF, render warfarin obselete?
